Drug intelligence / Profile preview

BAY3389934

Development stage: Phase 1
Lead developer: Bayer
Modality: Small Molecules
Administration: Intravenous

Overview

BAY3389934 is a potent and highly selective small molecule anticoagulant developed by Bayer. It acts as a direct dual inhibitor of factor IIa (thrombin) and factor Xa, two key enzymes in the blood coagulation cascade. The drug is being investigated primarily for the treatment of sepsis-induced coagulopathy (SIC) and other blood coagulation disorders. As a new molecular entity, it represents an innovative approach to anticoagulation by targeting both thrombin and factor Xa simultaneously, which may offer therapeutic advantages in conditions characterized by dysregulated clotting such as SIC[2][3][4][7][10].

Other names: BAY 3389934 hydrochlorideBAY3389934 hydrochlorideBAY-3389934 hydrochlorideCompound 31Compound31Compound-31

Targets

F2 (Thrombin)F10 (Factor Xa)

Beyond the preview

Go deeper on BAY3389934.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY3389934.

Explore the full profile